Small molecules inhibitors of IKK kinase activity

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 1, 2006, Pages 1-12

  Coish, Philip D G ^a   Wickens, Philip L ^a   Lowinger, Timothy B ^a  

^a BAYER CORPORATION   (United States)

Author keywords

Cancer; I B; IKK 1; IKK 2; IKK 3; Inflammation; NF B

Indexed keywords

2 AMINO 4H INDENO[1,2 B]THIOPHENE 3 CARBOXAMIDE; 4 PYRIDYLCYANOGUANIDINE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; AMIDE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; BMS 345541; CARBOLINE DERIVATIVE; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IMIDAZOLE DERIVATIVE; IMIDAZOQUINOXALINE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDIN 2 AMINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SC 514; SPC 839; THIAZOLE DERIVATIVE; THIENO[2,3 B]PYRIDINE 2 CARBOXAMIDE DERIVATIVE; THIOPHENE DERIVATIVE; THIOPHENECARBOXAMIDE DERIVATIVE; TPCA 1; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT ARTHRITIS; AUTOIMMUNE DISEASE; CLINICAL TRIAL; COMPLEX FORMATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IC 50; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; MULTIPLE MYELOMA; NONHUMAN; PATENT; PATHOGENESIS; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 30344449728     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.1.1     Document Type: Review

References (39)

1. KARIN M, YAMAMOTO Y, WANG QM: The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. Drug Disc. (2004) 3:17-26.
2. BURKE JR: Targeting IκB kinase for the treatment of inflammatory and other disorders. Curr. Opin. Drug Disc. Devel. (2003) 6:720-728.
3. HAEFNER B: NF-κB: arresting a major culprit in cancer. Drug Disc. Today (2002) 7:653-663.
4. VERMA IM, STEVENSON JK, SCHWARZ EM, VAN ANTWERP D, MIYAMOTO S: Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev. (1995) 9:2723-2735
5. BAEUERLE PA, BAICHWAL VR: NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv. Immunol. (1997) 65:111-137.
6. RAMAKRISHNAN P, WANG W, WALLACH D: Receptor-specific signaling for both the alternative and the canonical NF-κB activation pathways by NF-κB-inducing kinase. Immunity (2004) 21:477-489.
7. YAMAMOTO Y, GAYNOR RB: IκB kinases: key regulators of the NF-κB pathway. Trends Biochem. Sci. (2004) 29:72-79.
8. XIAO G, HARTHAJ EW, SUN SC: NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol. Cell. (2001) 7:401-409.
9. SENFTLEBEN U, CAO, Y, XIAO G et al.: Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science (2001) 293:1495-1499.
10. LI Q, ESTEPA G, MEMET S, ISRAEL A, VERMA IM: Complete lack of NF-κB activity in IKK1 and IKK2 double-deficient mice: additional defect in neurulation. Genes Dev. (2000) 14:1729-1733.
11. LI J, PEET GW, PULLEN SS et al.: Recombinant IκB kinases alpha and beta are direct kinases of IκBα. J. Biol. Chem. (1998) 273:30736-30741.
12. HU Y, BAUD V, DELHASE M et al.: Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science (1999) 284:316-320.
13. LI ZW, CHU W, HU Y et al.: The IKK beta subunit of I kappa B kinase (IKK) is essential for nuclear factor kappa B activation and prevention of apoptosis. J. Exp. Med. (1999) 189:1839-1845.
14. LI Q, VAN ANTWERP D, MERCURIO F, LEE KF, VERMA I: Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science (1999) 284:321-325.
15. PANDE V, RAMOS MJ: NF-κB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. Curr. Med. Chem. (2005) 12:357-374.
16. PALANKI MS, ERDMAN PE, REN M et al.: The design and synthesis of novel orally active inhibitors of AP-1 and NF-κB mediated transcription activation. SAR of in vitro and in vivo Studies. Bioorg. Med. Chem. Lett. (2003) 13:4077-4080.
17. BINGHAM AH, DAVENPORT RJ, GOWERS L et al.: A novel series of potent and selective IKK2 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(2):409-412.
18. BAXTER A, BROUGH S, COOPER A et al.: Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:2817-2822.
19. NO AUTHORS LISTED: Novel thiophenecarboxamide IKK-2 inhibitors. Expert Opin. Ther. Patents (2005) 15(3):343-347
20. PODOLIN PL, CALLAHAN JF, BOLOGNESE BJ et al.: Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5- (4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J. Pharmacol. Exp. Ther. (2005) 312:373-381.
21. KISHORE N, SOMMERS C, MATHIALAGAN S et al.: A selective IKK-2 inhibitor blocks NF-κX-dependent gene expression in interleukin-1β-stimulated synovial fibroblasts. J. Mol. Chem. (2003) 278(35):32861-32871.
22. JEONG S, PISE-MASISON C, RADONOVICH M, PARK H, BRADY J: A novel NF-κB pathway involving IKKβ and p65/RelA Ser-536 phosphorylation results in p53 inhibition in the absence of NF-κB transcriptional activity. J. Biol. Chem. (2005) 280(11):10326-10332.
23. MURATA T, SHIMADA S, SAKAKIBARA S et al.: Discovey of novel and selective IKK-β serine-threonine protein kinase inhibitors. Part 1. Bioorg. Med. Chem. Lett. (2003) 13:913-918.
24. MURATA T, SHIMADA M, KADONO H et al.: Synthesis and structure-activity relationships of novel IKK-β inhibitors. Part 2: improvement of in vitro activity. Bioorg. Med. Chem. Lett. (2004) 14:4013-4017.
25. MURATA T, SHIMADA M, SAKAKIBARA S et al.: Synthesis and structure-activity relationships of novel IKK-β inhibitors. Part 3: orally active antiinflammatory agents. Bioorg. Med. Chem. Lett. (2004) 14:4019-4022.
26. ZIEGELBAUER K, GANTNER F, LUKACS NW et al.: A selective novel low-molecular-weight inhibitor of IκB kinase-β (IKK-β) prevents pulmonary inflammation and shows broad anti-inflammatory activity Br. J. Pharmacol. (2005) 145:178-192.
27. BURKE JR, PATTOLI MA, GREGOR KR et al.: BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J. Biol. Chem. (2003) 278(3):1450-1456.
28. MACMASTER JF, DAMBACH DM, LEE DB et al.: An inhibitor of IκB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm. Res. (2003) 52:508-511.
29. TOWNSEND RM, POSTELNEK J, SUSULIC V et al.: A highly selective inhibitor of IκB kinase, BMS-345541, augments graft survival mediated by suboptimal immunosuppression in a routine model of cardiac graft rejection. Transplantation (2004) 77(7):1090-1094.
30. MCINTYRE KW SHUSTER DJ, GILLOOLY KM et al.: A highly selective inhibitor of IκB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. (2003) 48(9):2652-2659.
31. CASTRO AC, DANG LC, SOUCY F et al.: Novel IKK inhibitors: β-carbolines. Bioorg. Med. Chem. Lett. (2003) 13:2419-2422
32. LAM LT, DAVIS RE, PIERCE J et al.: Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin. Cancer Res. (2005) 11:28-40.
33. SCHOU C, OTTOSEN ER, PETERSEN HJ et al.: Novel cyanoguanidines with potent oral antitumor activity. Bioorg. Med. Chem. Lett. (1997) 7:3095-3100.
34. VIG HJARNAA PV, JONSSON E, LATINI S et al.: CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res. (1999) 59:5751-5757.
35. OLSEN LS, HJARNAA PV, LATINI S et al.: Anticancer agent CHS 828 suppresses nuclear factor-κB activity. Int. J. Cancer (2004) 111:198-205.
36. BINDERUP E, BJORKLING F, HJARNAA PV et al.: EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. Bioorg. Med. Chem. Lett. (2005) 15:2491-2494
37. KAMON J, YAMAUCHI T, MUTO S et al.: A novel IKKβ inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. Biochem. Biophys. Res. Commun. (2004) 323:242-248.
38. ONAI Y, SUZUKI J, KAKUTA T et al.: Inhibition of IκB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc. Res. (2004) 63:51.
39. TANAKA A, KONNO M, MUTO S et al.: A novel NF-κB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood (2005) 105(6):2324-2331.